Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. (Q51334840)

3 April 2018

title

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. (English)

1 reference

3 April 2018

1 reference

1 reference

9

1 reference

3 April 2018

Julio Rosenstock

6

object named as

Julio Rosenstock

1 reference

3 April 2018

8

Salim Yusuf

1 reference

3 April 2018

author name string

ORIGIN Trial Investigators

1

1 reference

3 April 2018

Linda G Mellbin

2

1 reference

3 April 2018

Lars Rydén

3

1 reference

3 April 2018

Matthew C Riddle

4

1 reference

3 April 2018

Jeffrey Probstfield

5

1 reference

3 April 2018

Rafael Díaz

7

1 reference

3 April 2018

publication date

2 September 2013

1 reference

3 April 2018

published in

European Heart Journal

1 reference

3 April 2018

volume

34

1 reference

3 April 2018

page(s)

3137-3144

1 reference

3 April 2018

issue

40

1 reference

3 April 2018

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Hypoglycemia and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Serious cardiovascular outcomes in diabetes: the role of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT332

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHT332

1 reference

3 April 2018

PubMed ID

23999452

1 reference

3 April 2018